Intrathecal drug delivery systems: A case series advancing surgical, clinical, and technological safety with broader implications for invasive neuromodulation therapies

Intrathecal drug delivery systems (IDDS) represent an advanced modality of invasive pharmacological neuromodulation, providing efficacious treatment for terminal malignant pain as well as select chronic noncancer pain conditions. Although intrathecal drug delivery systems offer the potential for reduced systemic adverse effects compared to conventional routes, they are not without significant complications, including infections, device dysfunction, and severe neurological injuries. Moreover, the integration of network-based smart-device applications into intrathecal drug delivery system control interfaces introduces a concomitant elevation in risks associated with software errors and cybersecurity vulnerabilities. Case 1: a 77-year-old male receiving intrathecal methadone therapy, after the failure of first- and second-line agents, developed a catheter-tip spinal granuloma resulting in irreversible paraplegia secondary to thoracic spinal cord compression. Case 2: a 37-year-old female with a history of longstanding depression experienced a severe surgical site infection attributable to suboptimal surgical techniques during intrathecal drug delivery system implantation. This complication led to septic shock and meningitis, necessitating device removal and prolonged intravenous antibiotic therapy, though she ultimately recovered without permanent neurological deficits. Case 3: a 67-year-old female encountered acute opioid withdrawal and subsequent hospitalization as a consequence of a tablet-based interrogation platform's software error in timekeeping that miscalculated her intrathecal drug delivery system refill date and recovered without enduring neurological sequelae. Invasive neuromodulation therapies, including intrathecal drug delivery systems, present multifaceted challenges that necessitate rigorous patient and therapeutic agent selection, meticulous risk factor mitigation, continuous neuromonitoring, and prompt detection of subtle neurological changes indicative of potential complications. This analysis delineates three critical domains: first, clinical vigilance and enhanced monitoring protocols are essential for the early identification of severe complications, such as granuloma formation; second, an educational paradigm shift, standardized, comprehensive surgical training in fellowship programs is required to ensure technical proficiency, optimal postoperative management, and an in-depth understanding of psychosocial factors; and third, technological leadership, the adoption of app-based management systems on consumer platforms introduces vulnerabilities including software malfunctions and cybersecurity threats, thereby necessitating that physicians advocate for stringent safety standards and robust regulatory oversight. Collectively, these strategies are indispensable for enhancing the safety and efficacy of invasive neuromodulation therapies and transforming the landscape of chronic pain management.